12th Edition of International Conference on
Neurology and Neurological Disorders
June 22-24, 2026 | Barcelona, Spain
Epilepsy and Seizure Disorders
Epilepsy and seizure disorders encompass a range of neurological conditions characterized by abnormal brain activity, leading to recurrent seizures. These disorders can vary in severity, from occasional, brief seizures to continuous, debilitating episodes. Advances in the understanding of epilepsy have focused on the genetic, environmental, and cellular mechanisms that contribute to the development of seizure activity, including ion channel dysfunction and neurotransmitter imbalances. Treatment strategies primarily involve antiepileptic drugs, but surgery, vagus nerve stimulation, and dietary therapies are also utilized for patients with refractory epilepsy. Ongoing research is investigating novel therapies, such as gene therapy and personalized medicine, to address the underlying causes of epilepsy and provide more effective treatments for seizure control and management.
Ken Ware
NeuroPhysics Therapy Institute, Australia
Robert B Slocum
University of Kentucky HealthCare, United States
Yong Xiao Wang
Albany Medical College, United States
Milton Cesar Rodrigues Medeiros
Hospital Santa Casa de Arapongas, Brazil
Zhenhuan Liu
Guangzhou University of Chinese Medicine, China
Jaqueline Tuppen
COGS Club, United Kingdom
Luiz Moutinho
University of Suffolk, United KingdomSubmit your abstract Today
Title : Perception and individuality in patient cases identifying the ongoing evolution of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Ken Ware, NeuroPhysics Therapy Institute, Australia
Title : Narrative medicine: A communication therapy for the communication disorder of Functional Seizures (FS) [also known as Psychogenic Non-Epileptic Seizures (PNES)]
Robert B Slocum, University of Kentucky HealthCare, United States
Title : Personalized and Precision Medicine (PPM), as a unique healthcare model through biodesign-driven biotech and biopharma, translational applications, and neurology-related biomarketing to secure human healthcare and biosafety
Sergey Victorovich Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Neuro sensorium
Luiz Moutinho, University of Suffolk, United Kingdom
Title : GBF1 inhibition reduces amyloid-beta levels in viable human postmortem Alzheimer's disease cortical explant and cortical organoid models
Sean J Miller, Yale School of Medicine, United States
Title : Traumatic Spinal Cord Injuries (tSCI) - Are the radiologically based “advances” in the management of the injured spine evidence-based?
W S El Masri, Keele University, United Kingdom